Informatie:
Fout:
ID
43590
Beschrijving
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline; ODM derived from: https://clinicaltrials.gov/show/NCT00506415
Link
https://clinicaltrials.gov/show/NCT00506415
Trefwoorden
Versies (2)
- 17-04-16 17-04-16 -
- 20-09-21 20-09-21 -
Geüploaded op
20 september 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Alzheimer Disease NCT00506415
Eligibility Alzheimer Disease NCT00506415
- StudyEvent: Eligibility
Similar models
Eligibility Alzheimer Disease NCT00506415
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
female; age; alzheimers disease
Item
male or female patients between 50 and 85 years of age with a diagnosis of probable alzheimers disease,
boolean
C0086287 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
C0002395 (UMLS CUI [2])
C0001779 (UMLS CUI [1,2])
C0002395 (UMLS CUI [2])
mini-mental state examination score
Item
baseline mini-mental state examination (mmse) score 10-24 inclusive,
boolean
C0451306 (UMLS CUI [1])
primary caregiver Compliance behavior
Item
a primary caregiver willing to accept responsibility for supervising treatment, assessing the patient's condition throughout the study, and for providing input into efficacy assessments.
boolean
C1319883 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,2])
mini-mental state examination score
Item
for double blind only: meet the decline criteria of functional (as assessed by the investigator) and cognitive (assessed by a 1 point reduction in mini-mental state examination) score between visits or a 3 point reduction from baseline) decline at weeks 23, 36 or 48.
boolean
C0451306 (UMLS CUI [1])
Compliance behavior Limited Comorbidity
Item
presence of an advanced, severe, progressive, or unstable disease of any type that could interfere with efficacy and safety assessments or put the patient at particular risk,
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
neurological condition; dementia
Item
any medical or neurological condition other than alzheimers disease that could explain the patient's dementia,
boolean
C0027765 (UMLS CUI [1])
C0497327 (UMLS CUI [2])
C0497327 (UMLS CUI [2])
vascular dementia
Item
a diagnosis of probable or possible vascular dementia,
boolean
C0011269 (UMLS CUI [1])
Compliance behavior Limited Comorbidity depression
Item
a current diagnosis of unsuccessfully-treated depression, or any other mental disorder that may interfere with the evaluation of the patient's response to study medication,
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0011570 (UMLS CUI [1,4])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0011570 (UMLS CUI [1,4])
cerebrovascular disease
Item
a history or current diagnosis of cerebrovascular disease (e.g. stroke),
boolean
C0007820 (UMLS CUI [1])
cardiovascular disease; coronary artery disease
Item
a current diagnosis of severe or unstable cardiovascular disease (e.g. unstable coronary artery disease).
boolean
C0007222 (UMLS CUI [1])
C1956346 (UMLS CUI [2])
C1956346 (UMLS CUI [2])
inclusion; exclusion criteria
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1512693 (UMLS CUI [1])
C0680251 (UMLS CUI [2])
C0680251 (UMLS CUI [2])